3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Gynecologic
1
Conditions
Ovarian Neoplasms
225
Uterine Cervical Neoplasms
181
Fallopian Tube Neoplasms
93
Carcinoma, Ovarian Epithelial
85
Endometrial Neoplasms
74
Neoplasms
37
Uterine Cervical Dysplasia
35
Papillomavirus Infections
35
Breast Neoplasms
26
Peritoneal Neoplasms
25
Vulvar Neoplasms
23
Condylomata Acuminata
22
Vaginal Neoplasms
18
Recurrence
16
Testicular Neoplasms
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Burkitt Lymphoma
12
Brenner Tumor
12
Primary Myelofibrosis
11
Multiple Myeloma
11
Lymphoma, Non-Hodgkin
11
Lymphoma, Mantle-Cell
11
Lymphoma, Large-Cell, Immunoblastic
11
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma, Follicular
11
Lymphoma, B-Cell, Marginal Zone
11
Leukemia, Myeloid, Chronic-Phase
11
Leukemia, Myeloid, Accelerated Phase
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Blast Crisis
11
Interventions
rucaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Genital Neoplasms, Male
×
Gynecologic
×
Clear all
NCT04676334
2024-05-07
CATCH-R
pharmaand GmbH
Phase 3
Completed
34 enrolled
9 charts